Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5948)
All Articles published online
|
Publishing Process of This Article
|
May 15, 2019 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(5): 424-435 [PMID: 31139312 DOI: 10.4251/wjgo.v11.i5.424] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v11/i5/424.htm |
| Number | Citing Articles |
| 1 |
Binquan Wu, Amin Li, Yinci Zhang, Xueke Liu, Shuping Zhou, Huaiyong Gan, Shiyu Cai, Yong Liang, Xiaolong Tang. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles. Expert Opinion on Drug Delivery 2020; 17(4): 573 doi: 10.1080/17425247.2020.1730809
|
| 2 |
Nathalie Théret, Fidaa Bouezzeddine, Fida Azar, Mona Diab-Assaf, Vincent Legagneux. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. Cancers 2021; 13(7): 1563 doi: 10.3390/cancers13071563
|
| 3 |
Von Willebrand Factor as a Biomarker for Liver Disease – An Update. Journal of Clinical and Experimental Hepatology 2023; 13(6): 1047 doi: 10.1016/j.jceh.2023.05.016
|
| 4 |
Chanukya K. Colonne, Emmanuel J. Favaloro, Leonardo Pasalic. The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer. Healthcare 2022; 10(3): 557 doi: 10.3390/healthcare10030557
|
| 5 |
Hiroaki Takaya, Tadashi Namisaki, Soichi Takeda, Kosuke Kaji, Hiroyuki Ogawa, Koji Ishida, Yuki Tsuji, Hirotetsu Takagi, Takahiro Ozutsumi, Yukihisa Fujinaga, Masanori Furukawa, Koh Kitagawa, Norihisa Nishimura, Yasuhiko Sawada, Naotaka Shimozato, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. The Combination of Albumin–Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child–Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. Journal of Clinical Medicine 2021; 10(21): 4838 doi: 10.3390/jcm10214838
|
| 6 |
Jiejun Hu, Dong Cai, Zhibo Zhao, Guo-Chao Zhong, Jianping Gong. Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.659676
|
| 7 |
Hiroaki Takaya, Tadashi Namisaki, Kei Moriya, Naotaka Shimozato, Kosuke Kaji, Hiroyuki Ogawa, Koji Ishida, Yuki Tsuji, Daisuke Kaya, Hirotestu Takagi, Yukihisa Fujinaga, Norihisa Nishimura, Yasuhiko Sawada, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji. Association between ADAMTS13 activity–VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. World Journal of Gastroenterology 2020; 26(45): 7232-7241 doi: 10.3748/wjg.v26.i45.7232
|
| 8 |
Hiroaki Takaya, Tadashi Namisaki, Shohei Asada, Satoshi Iwai, Takahiro Kubo, Junya Suzuki, Masahide Enomoto, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Yasuhiko Sawada, Kosuke Kaji, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability. Journal of Clinical Medicine 2022; 11(7): 1835 doi: 10.3390/jcm11071835
|